have been associated with variation in PSA concentrations (5 ) , several clinical and histomorphologic features of PCa (6 ) , and susceptibility to PCa (7 ) . A genomewide association study provided early evidence of the association with PCa (8 ) . The association with PCa is controversial, however, because susceptibility to PCa could be related to PSA-based case ascertainment, with the reported risk of PCa being mediated through the effect of KLK3 genetic variation on PSA concentrations (9, 10 ) . A subsequent genomewide association study and follow-up analysis have shown a tendency for a KLK3 SNP allele associated with PCa risk also to be associated with high PSA concentrations (10 ) . In addition, a recent 2-stage genomewide association study showed a direct association between a novel KLK3 SNP and PCa (11 ) . These results are consistent with a direct influence of common genetic variation in KLK3 on PCa, because the majority of the control samples were not selected on the basis of PSA concentrations, making it less likely that the association with PCa is a reflection of an association with PSA concentrations.
The combined effect of genetic variants for 4 genes associated with PSA concentrations [TERT (telomerase reverse transcriptase), FGFR2 (fibroblast growth factor receptor 2), TBX3 (T-box protein 3), and KLK3] has been studied in 2 populations (in Iceland and the UK), on the assumption of a multiplicative model. For the lowest 5% of the genetic PSA distribution, the PSA concentrations were estimated to be lower than the population mean by 30%-56% in the Icelandic population and by 53%-80% in the UK population (10 ) . This combined effect, however, does not explain the very low PSA concentrations (Յ0.1 g/L) found in some individuals.
Two recent studies have resequenced KLK3 and neighboring genes from samples obtained from PCa patients and control individuals (12, 13 ) . Parikh et al. (12 ) identified 555 polymorphic loci within the region containing KLK3 and the neighboring genes KLK15 and KLK2, including 116 novel SNPs, 182 novel insertion-deletion (indel) polymorphisms, and 257 previously described loci. Klein et al. (13 ) identified 140 polymorphisms in all 15 kallikrein genes, including 38 novel SNPs. None of these studies described any major rearrangements (deletion or insertion) in KLK3. In addition, no study published to date has investigated genetic variation, either at the sequence level or at the level of major genetic rearrangements, in a selected group of individuals with very low PSA concentrations.
Our hypothesis is that very low serum PSA concentrations may reflect inactivating gene mutations or gross genetic rearrangements involving KLK3. To test this hypothesis, we conducted a detailed genetic analysis of 30 individuals with the lowest observed PSA concentrations (Յ0.1 g/L) in a cohort of approximately 85 000 men from the Prostate Testing for Cancer and Treatment (ProtecT) study (14 ) .
Materials and Methods

INFORMATION ABOUT THE ProtecT STUDY
In the ProtecT study, approximately 85 000 men 50 -69 years of age were randomly selected from 300 randomly selected general practices in 9 UK cities (broadly representing the UK white population). These men then underwent testing in PSA-testing clinics. From the results, 2000 PCa cases and 2000 controls were randomly selected to form one of the largest PCa case control studies in the world (15, 16 ) .
Men from specific primary-care centers in the cities were invited to attend a 30-min clinic appointment for a prostate check, at which time they were informed about the study and asked to consent to a PSA test. Men with an increased PSA concentration (initially Ͼ3.0 g/L if 50 -59 years of age and Ͼ4.0 g/L if 60 -69 years of age; however, the cutoff was changed to Ͼ3.0 g/L for all men after 1 year) were invited for biopsy. Histologically confirmed PCa cases were identified through a combination of PSA testing, digital rectal examination, and, for men with abnormal PSA concentrations or digital rectal examination findings, a 10-core transrectal ultrasound-guided biopsy.
The inclusion criteria for this study were absence of PCa, PSA concentrations Յ0.1 g/L, and availability of DNA. These criteria defined a sample of 30 individuals in the ProtecT study.
SERUM PSA MEASUREMENTS
In the ProtecT study, the testing of serum PSA concentrations was overseen by the UK National External Quality Assessment Service (NEQAS), which provided quality assessment of the PSA tests performed in all immunology departments for the different ProtecT locations. We used 2 different immunoassays [ADVIA Centaur (Siemens Healthcare Diagnostics) and Elecsys (Roche)] for repeated PSA measurements in all 30 selected individuals. PSA measurements with the ADVIA Centaur and Elecsys systems were performed at Southmead Hospital, Bristol, UK, and in accordance with the recommendations of the 2 immunoassays' manufacturers. Both methods meet the criteria for acceptable performance, as determined by the Centre for Evidence-based Purchasing (National Health Service Purchasing and Supply Agency), with respect to accuracy and equimolarity (equivalent abilities to detect the free and complexed forms of PSA) (17 ) . The degree of agreement between the 2 methods was assessed with Pearson correlation coefficients.
PCR AMPLIFICATION AND SEQUENCING
We sequenced all exons and the regulatory region of KLK3 to search for genetic defects in KLK3 that would lead to abnormal PSA concentrations. We designed 4 long-PCR assays encompassing KLK3 and its regulatory regions (for primers and PCR conditions, see Appendix 1 in the Data Supplement that accompanies the online version of this article at http://www. clinchem.org/content/vol59/issue1). Long PCRs were followed by nested PCRs to generate PCR products, which were then outsourced for sequencing to GATC Biotech (http://www.gatc-biotech.com). The quality of chromatograms was analyzed before the alignment of all sequences to a reference sequence (see Appendix 2 in the online Data Supplement).
ASSESSMENT OF THE EFFECTS OF THE OBSERVED VARIANTS
Details of the methods used to assess the effects of the observed variants are described in Appendix 3 in the online Data Supplement. NNSplice, SpliceView, SplicePort, and Human Splicing Finder were used for predicting splice sites, and the SNP-prediction tools SIFT, PolyPhen-2, SNPs3D, PMut, and SNPs&GO were used to assess for nonsynonymous variants).
GROSS REARRANGEMENTS
We also looked for gross rearrangements (deletions and duplications) in the KLK3 gene by means of a highthroughput ratiometric method, the amplification ratio control system (ARCS), which we developed and validated in our laboratory to genotype copy number variants (18 ) . This method is based on a novel PCR protocol that analyzes the ratio of the number of copies of a gene with a variable copy number to a single-copy reference gene. The amplicons for the target and reference genes were designed to have melting temperatures that differed by a few degrees Celsius to enable their differentiation in a melting assay. The ratio of the copy number of the target gene to the reference gene is inferred from the change in fluorescence contributed by each gene as it undergoes melting. We designed ARCS assays for KLK3 exons and neighboring genes both upstream and downstream (see Appendix 4 in the online Data Supplement for primers and PCR conditions). Table 1 shows serum PSA concentrations for all 30 ProtecT participants measured with the Centaur and Elecsys immunoassays for the same samples, compared with the initial PSA concentrations. The measurements obtained with the 2 immunoassays were in close agreement (Pearson r, 0.987). All measurements were Ͻ0.5 g/L, with the exception of 2 individuals (S5 and S17), whose reassay results were approximately 0.8 g/L and 1.2 g/L, respectively. The data for these 2 individuals were also included in our analysis. Note that the PSA concentrations in both instances are much lower (approximately 1 to 1.5 SDs lower) than the population mean observed for healthy men of different ages [mean (SD), 2.9 (1.7) g/L for men 60 -69 years of age and 2.0 (1.2) g/L for men 50 -59 years of age] (19 ). 
Results
SERUM PSA CONCENTRATIONS
GENETIC VARIATION AT THE SEQUENCE LEVEL
We detected 30 genetic variants in the KLK3 region: 25 SNPs, 2 indels, and 3 previously unreported SNPs (Table 2). Also shown are the observed genotype frequencies in our study. We identified 9 polymorphic loci in the regulatory regions upstream of KLK3 (Table 2 ). Two were indels: an A insertion (rs17554958) in the proximal promoter and a C insertion (rs57268074) in the KLK3 enhancer. One variant was a previously unreported C-to-A variant at an SNP locus for a reported C-to-G SNP (rs73932613) adjacent to rs17554958. Two variants were SNPs within androgen-responsive elements (ARE): rs266882 in ARE I and rs11084033 in the nonconsensus ARE VI. The 4 other SNPs upstream of KLK3 were rs3760722, rs17526278, rs4802754, and a previously unreported SNP (minor-allele frequency, 0.44).
Nine coding variants were found in KLK3 exons-5 synonymous and 4 nonsynonymous variants (Table 2) . The nonsynonymous variants include a previously unreported C-to-T variant in exon 3, which encodes the substitution of a tryptophan residue for an arginine residue at position 77 (Arg77Trp) in PSA. Two other missense mutations were found in KLK3 exon 3: rs61752561 (Asp102Asn), and rs2003783 (Leu132Ile). The KLK3 exon 4 SNP (rs17632542) encodes the Ile179Thr variant in PSA. We also detected a synonymous T-to-C variant (rs11573) within KLK3 exon 2. The remaining 12 variants (Table 2 ) consisted of 7 intronic polymorphisms, 5 of which are previously reported SNPs in the 3Ј untranslated region. The intronic SNPs include 2 that are previously unreported: a G-to-A variant in intron 4 and a T-to-G variant in intron 5 (see Fig. 1 in the online Data Supplement for the genotypes for all 30 variants observed in the 30 individuals).
CONSEQUENCES FOR SPLICING
The synonymous T-to-C mutation (rs11573) is 2 bp downstream of the 3Ј end of intron 1. This variant has previously been reported in the dbSNP database as a KLK3 splice site variant, although it is not in the splice consensus sequence region (i.e., it is not within the obligatory dinucleotide essential for effective recognition of the acceptor site at the 3Ј end of intron 1).
On the other hand, our results obtained with splicing-prediction tools show that 1 of the 30 sequence variants we detected (rs7252245) lies within a predicted splice site (see Table 1 in the online Data Supplement). All of the other variants we detected are located at least 10 bp away from the predicted acceptor or donor splice sites (see Table 1 in the online Data Supplement). Table 2 in the online Data Supplement shows the FASTA sequence of KLK3, annotated splice sites, and SNPs identified in the present work. Table 3 shows the predicted effects of the 4 nonsynonymous variants on protein function. The novel Arg77Trp variant in exon 3 shows evidence that is has probable damaging effects. All 5 prediction tools used in this study predicted this variant as "damaging (pathological)," with the PMut tool predicting the most pathologic (i.e., maximum) effect at position 77. SNPs&GO predicted this variant to be a "disease" variant, although the reliability of this prediction was remarkably low (Reliability Index ϭ 1). Similarly, the Asp102Asn and Leu132Ile replacements were variously described as "tolerated" (SIFT), "neutral" (PMut), and "benign" (PolyPhen-2) ( Table 3 ). The outcomes for the SNPs&GO prediction tool for the Asp102Asn and Leu132Ile variants were in line with those for other tools. Conflicting results were observed for the Ile179Thr substitution in the protein sequence. This variant was predicted as damaging by both SIFT (score, 0.01; 136 sequences queried) and SNPs3D [score, Ϫ2.45 for the 261-residue polypeptide chain (including pre-and pro-PSA) and Ϫ2.39 for the active protein comprising 238 residues] (Table 3) , with SNPs3D predicting a loss of hydrophobicity at the molecular level.
PHENOTYPIC CONSEQUENCES OF NONSYNONYMOUS VARIANTS
On the other hand, PMut ranked this variant as "neutral" (NN output, 0.3185; Reliability Index, 3), SNPs&GO predicted it as "neutral," with a moderate Reliability Index (5 of a maximum of 9), and PolyPhen-2 ranked it as "benign" (score, 0.152; sensitivity, 0.91; specificity, 0.83). Table 4 presents the P values obtained for comparisons of our allele counts with European data from the dbSNP database, with data from Parikh et al. (12 ) , and with both data sets combined. Comparisons were not possible for 3 polymorphisms that no frequency data reported in either dbSNP or Parikh et al. (12 ) . These polymorphisms are the far-upstream indel rs57268074, the novel C-to-T variant in the ARE II region, and the novel C-to-T variant encoding the Arg77Trp substitution. Note that the allele frequencies of the splice variants rs11573 and rs7252245 were not significantly different from the allele frequencies reported in dbSNP and by Parikh et al. (12 ) (see Table 4 ).
COMPARISON OF ALLELE FREQUENCIES
Only 2 variants in our resequencing data were significantly different in frequency from those in both the dbSNP database and the findings of Parikh et al. (12 ) : the intronic SNP rs174776 (T to C) and the 3Ј untranslated region SNP rs1058205 (C to T). The minor allele in the latter SNP was significantly overrepresented in our sample (P ϭ 0.007, compared with the dbSNP data; P ϭ 0.003, compared with the data of Parikh et al. (12 ) ; P ϭ 0.002, compared with the 2 data sets combined). The allele frequencies of 2 additional SNPs [the intronic SNP rs1810020 (A to G) and the 3Ј untranslated region SNP rs2659122 (C to T)] were significantly different from frequencies reported by Parikh et al. (12 ) but not from those reported in the dbSNP database. When data from both sets were combined, the resulting frequencies were statistically different from the allele frequencies for these 2 loci in our sample (Table 4) ; however, none of these significant differences withstand the Bonferroni correction for multiple testing (␣ Bonferroni ϭ 0.05/71 ϭ 0.0007). Fig. 2 in the online Data Supplement shows the alignment of the nucleotide and amino acid sequences with annotated variants (our nucleotide sequence variants are represented below). The sequences are also aligned with the protein's secondary structure (obtained from the Protein Data Bank) to put the amino acid substitutions into the context of PSA structural features in which they are located. No evidence of novel genetic variation leading to changes in PSA concentrations was apparent from possible changes in PSA secondary structure.
PROTEIN SECONDARY STRUCTURE
LARGE DELETIONS SPANNING THE WHOLE OF KLK3
Three of the 30 participants with very low PSA concentrations (Յ0.1 g/L) were heterozygous for different major deletions that spanned all KLK3 exons. Fig. 1 shows an example of the evidence for these deletions for these 3 individuals. Individual S7 showed deletion of all KLK3 exons (see Appendix 5 in the online Data Supplement) and the neighboring gene KLK15 (upstream of KLK3). There was no evidence of deletion of the downstream gene KLK2 (exon 2). All of KLK3 was deleted in individual S8, along with KLK15 and KLK1 (upstream of KLK3), and KLK2 (downstream of KLK3) (see Appendix 5 in the online Data Supplement). Individual S23 showed evidence of deletion of all of KLK3, along with a long region upstream of KLK3 that included KLK15, KLK1, ACPT (acid phosphatase, testicular), and GPR32 (G protein-coupled receptor 32). The last 2 genes are outside the kallikrein gene cluster. S23 also showed partial deletion of KLK2 (see Appendix 5 in the online Data Supplement). This finding confirmed heterozygosity for total deletion of KLK3 in both individuals. Fig. 2 shows a schematic of the extents of the 3 deletions found in this study. Each exon assay result represents independent confirmation of the occurrence of a gross deletion in the KLK3 region in these individuals.
Discussion
This study is the first detailed characterization of single-nucleotide genetic variations and gross rearrangements involving KLK3 in individuals with very low PSA concentrations. Our study confirms the existence of 3 novel deletions. ARCS ratiometric analyses of KLK3 exons and neighboring genes enabled us to determine that these deletions span the whole of KLK3. These deletions represent the first described human deletion mutants of KLK3 and have important implications for interpreting PSA test results with respect to PCa for some individuals.
No frameshift mutations and no premature stop codons, which might be causes of very low PSA concentrations, were observed in our sequence data. The data on KLK3 genetic variation in the dbSNP database (http://www.ncbi.nlm.nih.gov/projects/SNP/ snp_ref.cgi?locusIdϭ354) includes records of 2 previously reported indels in KLK3 that may cause frameshift mutations. In the indel locus rs17849961, a GC pair is replaced by a single nucleotide. The other reported frameshift mutation is rs34953540; an _/A indel polymorphism. None of these indels were found in our sample set, and no associations between these indels and serum PSA concentrations have been reported in the literature.
Alternative splicing (20 ) and intron-retention (21 ) events have been described for KLK3. The results 2 comparisons with frequency data from the dbSNP database and Parikh et al. (12 ) combined. h Frequency data are based on the reported C/G variant; a C/A variant was detected at the same locus in our study. i _/C and _/A are insertion mutations. j Named as CGF_33864 in Parikh et al. (12 ) .
of our analyses with splicing-prediction tools show that most of the 30 sequence variants detected in our work are not within KLK3 acceptor or donor sites. We observed in our study 2 genetic variants within splice sites (rs11573 and rs7252245). Both are in exon 2, far apart from the putative donor and acceptor sites involved in the retention of intron 3 in the PSA rp-2 transcript (21 ). These findings rule out the possibility of an influence of these variants on intron 3 retention. In addition, the allele frequencies of one of these SNPs (rs11573) were not significantly different from those reported in dbSNP. This finding suggests that this SNP is not a cause of very low PSA concentrations. If it were, we would expect an overrepresentation of 1 allele in our selected sample. We observed rs7252245 allele A in only 2 individuals and only in heterozygosis; therefore, it could not explain the very low PSA concentrations observed in all 30 samples.
On the other hand, the polymorphism in the polypyrimidine tract in the noncoding intron I near the 3Ј splice site of the INS (insulin) gene has been reported to affect pre-mRNA splicing and proinsulin secretion. The A allele of the INS gene restriction fragment length polymorphism Ϫ23HphI leads to retention of intron 1, and the extended mRNAs generate 6-fold more proinsulin in culture supernatants than natural transcripts (22, 23 ) . This new type of polymorphism has been termed "splicing and translational efficiency polymorphism" (STEP) (24 ) . A database including 3324 candidate STEPs is available online (25 ) . Therefore, it is possible that DNA sequence variation at or near splice sites within KLK3 could explain differences in PSA concentrations; however, no STEP in the online STEP database has been identified within KLK3 (25 ) .
The finding of nonsynonymous variants raises the possibility of functional effects on PSA. We found good agreement in general among the results obtained with the SIFT, PolyPhen-2, SNPs3D, PMut, and SNPs&GO tools. An interesting finding of our work is a previously unreported missense variation (Arg77Trp in exon 3). This substitution may be functionally inactivating, but we have no evidence at this stage that it leads to very low PSA concentrations.
Therefore, we cannot confidently conclude whether any of the single-base variants detected in this work markedly lower PSA concentration or activity.
The allele frequencies observed for 2 SNPs in our study were significantly different from those reported in the dbSNP database and by Parikh et al. (12 ) ; however, these significant differences may be type I errors associated with multiple testing. In addition, if these differences were real, it would be very unlikely that they accounted for the very low concentrations observed in our samples, given the relatively reduced magnitude of effect previously observed for common variants in KLK3 and in other genes that influence serum PSA concentrations (10 ) .
Further work is needed to define the spectrum of allelic inactivation in the wider population and the precise locations of breakpoints for the deletions. We note at this stage that at least 1 carrier of the heterozygous KLK3 mutation was fertile. Overall, the number of offspring for these 30 individuals also was consistent with the national average. The same KLK3 deletion carrier Each sample has 2 peaks. The peak on the left represents the AT-rich reference amplicon (typically melts at 65°C with 200 mL/L formamide). The peak on the right represents the amplicon for KLK3 exon 3 (melts at 70°C with 200 mL/L formamide). The reference peaks for the 3 samples are similar, whereas the target gene (KLK3 exon 3) shows variation. Three samples (S7, S8, and S23) show lower peaks than the control samples (S15, S14, and S3). This result is consistent with the occurrence of a heterozygous deletion in S7, S8, and S23. ϪdF/dT, first negative derivative of fluorescence, F, with respect to time, T.
had also undergone transurethral resection for benign prostatic disease.
A point to add is that the individuals in whom we have identified gross deletions in KLK3 display very low PSA concentrations, a finding that raises questions about the actual activity of the enzyme encoded by the nondeleted allele. Results from our study show that there is not a good correlation with a dosage effect. A correlation would be expected if heterozygotes for the deletion had PSA concentrations intermediate between zero and the concentrations in those homozygous for nondeletion. Our results did not allow us to determine whether these individuals show low expression of the other allele or whether it might also be affected. It is possible that other alterations (e.g., changes in gene regulation) are affecting the other allele in these individuals with very low PSA concentrations but that they were not detectable in our survey. One hypothesis for the very low PSA concentrations found in the carriers of a single copy of one of these deletions could be a dominant loss-of-function effect. An example is retinitis pigmentosa, in which there are 2 wild-type alleles (a high-expression allele and a low-expression allele). The combination of a mutant allele with a high-expression allele produces no disease phenotype, whereas the presence of a mutant allele and the low-expression allele produces protein concentrations below those required for normal function, thereby causing the disease (26 ) .
On the other hand, results obtained with exome chips (ftp://share.sph.umich.edu/exomeChip/Proposed Content/codingContent) have indicated the occurrence of stop codons in several KLK genes, including KLK4, KLK9, KLK10, and KLK14. That would be consistent with fewer functional constraints in this cluster, which would increase the frequency of gene inactivations compared with other genomic regions.
The PSA test is routinely used to diagnose and monitor PCa, with at least 40 million PSA tests having been carried out worldwide in 2007 alone (27 ) . Our findings confirmed our hypothesis that very low PSA concentrations could be caused by a major mutation in KLK3 in some individuals. Such low expressors may be at a disadvantage in PSA-based biomarker diagnosis, monitoring, and screening tests, in that their haploinsufficiency leads to false-negative results, and therefore false reassurance. Given that SNP variation in KLK3 seems to mark PCa risk as well as PSA concentrations (10 ), major allelic mutations may also participate in affecting PCa risk or benign prostatic disease.
Although our study has shown a relatively low frequency of deletions and our analysis has been based on a sample of individuals with extreme PSA concentrations, it is important to recognize that deletions can occur and produce false-negative results in PCa screening programs. Future studies with large population cohorts are required to determine the frequency of KLK3 deletions in the general population.
The identification of deletion mutants opens up the possibility of new ways to explore the role of the KLK3 gene in PSA function. These results enable analyses of the effect of KLK3 dose on its expression. They also enable the characterization of the phenotypic consequences associated with KLK3 deletion. In addition, our observations reinforce the concept that copy num- Very Low PSA and KLK3 Deletions ber variants play important roles in diverse medical contexts, in this instance regarding a leading biomarker and a possible factor contributing to benign prostatic hyperplasia and PCa.
